Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothelial Cell Permeability

Exosomes released by Cerebrolysin-treated cerebral endothelial cells (Cerebro-Exos) restored the integrity of cultured endothelial cells impaired by fibrin and tissue plasminogen activator, and did so better than exosomes from untreated cells. Their cargo was enriched in metabolic and tight junction proteins, and treatment shifted challenged cells toward reduced inflammation/coagulation proteins and increased tight junction/metabolism proteins. This was an in vitro study and did not test Cerebrolysin in patients.

Journal article — in vitro experimental permeability study. Population: cultured cerebral endothelial cells with fibrin- or tPA-impaired permeability. Interventions: Cerebro-Exos (exosomes from Cerebrolysin-treated cerebral endothelial cells).

Stoichiometric analysis showed marked cargo differences between Cerebro-Exos and Naïve-Exos, with Cerebro-Exos enriched in metabolic and tight junction proteins. Cerebro-Exos were superior to Naïve-Exos in restoring CEC integrity impaired by fibrin and tPA. In fibrin- and tPA-challenged CECs, Cerebro-Exos reduced inflammation- and coagulation-related proteins that were augmented by fibrin/tPA and increased tight junction- and metabolism-related proteins that were decreased by fibrin/tPA. No quantitative values are reported in the abstract.

Researchers studying Cerebrolysin would care because this paper identifies a potential paracrine mechanism: exosomes from Cerebrolysin-treated endothelial cells carry protective cargo and can reverse fibrin/tPA-induced barrier dysfunction in cultured cerebral endothelial cells. It does not establish that this exosome pathway operates in vivo or that Cerebrolysin has clinical benefit through this mechanism.

Key findings

• Cerebro-Exos were highly enriched in metabolic and tight junction-related proteins compared with Naïve-Exos.
• Cerebro-Exos had a superior effect compared with Naïve-Exos on restoring CEC integrity impaired by fibrin and tPA.
• Cerebro-Exos robustly reduced fibrin- and tPA-augmented proteins involved in inflammation and coagulation.
• Cerebro-Exos substantially increased fibrin- and tPA-decreased proteins related to tight junctions and metabolism.
• Stoichiometric analysis showed marked differences in cargo profiles between Cerebro-Exos and Naïve-Exos.

Limitations

• In vitro cell-culture design limits translation to in vivo and clinical settings.
• No quantitative data, sample size, dose, or duration are reported in the abstract.
• The study does not test whether Cerebrolysin itself produces these exosome effects in vivo.
• Clinical efficacy of Cerebrolysin or Cerebro-Exos is not established.

The record

• Journal: Cells 15(10): 934
• Published: 2026-05-19
• PMID: 42193943 — DOI: 10.3390/cells15100934
• MeSH terms: Brain, Endothelial Cells, Animals, Humans, Tissue Plasminogen Activator, Amino Acids, Fibrin, Exosomes
• Funding: EVER Pharma GmbH, Oberburgau 3, Unterach, Austria.
• Author countries: USA

Peptide profiles: Cerebrolysin.

All indexed evidence: Cerebrolysin trials & papers.

Related studies: Impact of N-PEP-12 Supplementation on Attentional Performance and Mental Wellbeing in…, Retraction Note: Cerebrolysin Attenuates Exacerbation of Neuropathic Pain, Blood-Spinal…, Retraction: Regional Comparison of the Neurogenic Effects of CNTF-Derived Peptides and….